Author

Jennifer Sealey Voyksner

CELIACSHIELDTM GLUTEN-CHALLENGE STUDY – LATIGLUTENASE PROTECTS THE MUCOSA AND ATTENUATES SYMPTOMS IN CELIAC DISEASE PATIENTS
CELIACSHIELDTM GLUTEN-CHALLENGE STUDY – LATIGLUTENASE PROTECTS THE MUCOSA AND ATTENUATES SYMPTOMS IN CELIAC DISEASE PATIENTS

Jennifer Sealey Voyksner

LATIGLUTENASE – AN EFFECTIVE ORAL THERAPY IN DEVELOPMENT FOR THE TREATMENT OF CELIAC DISEASE: EXPLORING THE BENEFITS AND CHALLENGES OF ADMINISTERING AND MEASURING GLUTEN IN A CLINICAL TRIAL SETTING
LATIGLUTENASE – AN EFFECTIVE ORAL THERAPY IN DEVELOPMENT FOR THE TREATMENT OF CELIAC DISEASE: EXPLORING THE BENEFITS AND CHALLENGES OF ADMINISTERING AND MEASURING GLUTEN IN A CLINICAL TRIAL SETTING

CELIACSHIELD(TM) GLUTEN CHALLENGE STUDY - GLUTEN IMMUNOGENIC PEPTIDE MEASUREMENTS IN URINE VALIDATE THE LATIGLUTENASE MECHANISM OF ACTION AND PROVIDE A MEASURE OF COMPLIANCE IN A CLINICAL TRIAL SETTING
CELIACSHIELD(TM) GLUTEN CHALLENGE STUDY - GLUTEN IMMUNOGENIC PEPTIDE MEASUREMENTS IN URINE VALIDATE THE LATIGLUTENASE MECHANISM OF ACTION AND PROVIDE A MEASURE OF COMPLIANCE IN A CLINICAL TRIAL SETTING

LATIGLUTENASE – AN EFFECTIVE ORAL THERAPY IN DEVELOPMENT FOR THE TREATMENT OF CELIAC DISEASE: EXPLORING THE BENEFITS AND CHALLENGES OF ADMINISTERING AND MEASURING GLUTEN IN A CLINICAL TRIAL SETTING
LATIGLUTENASE – AN EFFECTIVE ORAL THERAPY IN DEVELOPMENT FOR THE TREATMENT OF CELIAC DISEASE: EXPLORING THE BENEFITS AND CHALLENGES OF ADMINISTERING AND MEASURING GLUTEN IN A CLINICAL TRIAL SETTING

Jennifer Sealey Voyksner  et al.

CELIACSHIELD (TM) GLUTEN CHALLENGE STUDY – GLUTEN IMMUNOGENIC PEPTIDE MEASUREMENTS IN URINE VALIDATE THE LATIGLUTENASE MECHANISM OF ACTION AND PROVIDE A MEASURE OF COMPLIANCE IN A CLINICAL TRIAL SETTING
CELIACSHIELD (TM) GLUTEN CHALLENGE STUDY – GLUTEN IMMUNOGENIC PEPTIDE MEASUREMENTS IN URINE VALIDATE THE LATIGLUTENASE MECHANISM OF ACTION AND PROVIDE A MEASURE OF COMPLIANCE IN A CLINICAL TRIAL SETTING

Jennifer Sealey Voyksner  et al.

Item 1 - 5 / 5
1